"Hubble Lens" May Be Next IOL For AMD

by Dan Roberts London Eye Hospital Pharma announced today that it has initiated U.S. discussions to gain clinical data for its iolAMD lens system.  iolAMD is a novel intraocular lens (IOL) system designed to restore lost vision and provide an independent lifestyle for patients with dry AMD and related diseases. The technology behind the iolAMD lens [Read More]

Stem Cell Trial Yields Surprising Results

by Dan Roberts Advanced Cell Technology, Inc. (now owned by Astellas) has been conducting promising safety trials for stem cell treatment of macular degeneration, but a six-month follow up has yielded even better news than expected. ACT announced that Phase 1/2 clinical data treatment of Stargardt’s macular degeneration (SMD) and dry age-related macular degeneration (AMD). Surprising even [Read More]

FDA Grants Priority Review for Lucentis in Diabetic Retinopathy

Genentech has announced that the FDA has granted its submission for Priority Review of Lucentis® (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015. If approved, Lucentis could be the first eye medicine available for diabetic retinopathy patients. Lucentis [Read More]

FDA Approves Two Extended-Release Drug Therapies For DME

By Dan Roberts Implants devised by two different companies for treatment of diabetic macular edema (DME) have been approved by the FDA for use in the United States. The companies are Allergan and Alimera, and the new drugs are Ozurdex and Iluvien respectively. Both drugs are corticosteroids that have demonstrated effectiveness in the treatment of [Read More]